SynthesisHuman vaccines & immunotherapeutics2026
Epidemiological characteristics of rotavirus gastroenteritis in China: A systematic review of studies published from 2014 to 2023.
Synthesis in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus gastroenteritis (RVGE) is a major public health concern, particularly amongst children below five-years-old. In China, the disease burden remains high owing to the absence of a comprehensive detection system. This study analyses RVGE incidence, population distribution, and pathogenic genotypes reported in studies published between 2014 and 2023, providing evidence to support vaccine and drug development. A systematic review of studies on RVGE published between 2014 and 2023 was conducted. Articles were screened using a standardized algorithm. A random-effects model was employed to analyze rotavirus positive rates and genotype variation trends. Among 320 studies, the highest rotavirus positive rates in children (≤5 y) were in Jilin (48.59%), Shanxi (40.89%), and Xinjiang (37.65%), while the highest number of infections were in Yunnan (89,128), Jiangsu (82,869), and Guangxi (36,524). Among adults (≥15 y), Shaanxi (27.73%), Inner Mongolia (22.95%), and Heilongjiang (17.82%) had the highest rotavirus positive rates, whereas Shanghai (3,170), Beijing (2,019), and Fujian (1,044) recorded the most infections. The rotavirus positive rates were 26.46% and 32.85% for children visiting the outpatient/emergency department and the inpatient department, respectively. Before 2018, the dominant G genotypes were G9 (children: 42.89%; adults: 56.13%) and G3 (children: 20.17%; adults: 14.71%), whereas the dominant P genotype was P[8] (children: 76.30%; adults: 80.78%). After 2018, G9 (children: 66.73%; adults: 67.43%) and P[8] (children: 88.62%; adults: 88.57%) became predominant in both groups, with an increase in G8 (before: 0.89%; after: 5.08%) among children. RVGE remains a significant burden in China, with evolving distributions. Continuous surveillance is essential to guide vaccine strain selection and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.